{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:58:15Z","timestamp":1793836695835,"version":"4.6.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.semarthrit.2024.152474","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T12:37:19Z","timestamp":1717418239000},"page":"152474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Janus kinase inhibition (JAKi) therapy in refractory anti-synthetase syndrome: A retrospective cohort study"],"prefix":"10.1016","volume":"68","author":[{"given":"Xueyan","family":"Shan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3674-9307","authenticated-orcid":false,"given":"Yongpeng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10379","key":"10.1016\/j.semarthrit.2024.152474_bib0001","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152474_bib0002","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152474_bib0003","first-page":"130","article-title":"New insights into antisynthetase syndrome","volume":"11","author":"Cojocaru","year":"2016","journal-title":"Maedica (Bucur)"},{"key":"10.1016\/j.semarthrit.2024.152474_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.866087","article-title":"Aminoacyl-tRNA synthetases: on anti-synthetase syndrome and beyond","volume":"13","author":"Galindo-Feria","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.semarthrit.2024.152474_bib0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/1744666X.2018.1491307","article-title":"TreaTMENT OF INFLAMMATORY MYOPAThies","volume":"14","author":"Pipitone","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152474_bib0006","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00296-023-05302-9","article-title":"Rituximab as the first-line therapy in anti-synthetase syndrome-related interstitial lung disease","volume":"43","author":"Zeki\u0107","year":"2023","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2024.152474_bib0007","article-title":"Antisynthetase syndrome-associated interstitial lung disease: monitoring of immunosuppressive treatment effects by chest computed tomography","volume":"7","author":"Korsten","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152474_bib0008","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3899\/jrheum.170541","article-title":"Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review","volume":"45","author":"Doyle","year":"2018","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152474_bib0009","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.3899\/jrheum.190505","article-title":"Rituximab and cyclophosphamide in antisynthetase syndrome-related interstitial lung disease: an observational retrospective study","volume":"47","author":"Langlois","year":"2020","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152474_bib0010","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/ard-2022-222784","article-title":"Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update","volume":"82","author":"Aletaha","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152474_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109044","article-title":"Effect of Baricitinib on the epithelial-mesenchymal transition of alveolar epithelial cells induced by IL-6","volume":"110","author":"Liu","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152474_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003599","article-title":"Long-lasting improvement of refractory antisynthetase syndrome with tocilizumab: a report of two cases","volume":"9","author":"Baumann Benvenuti","year":"2023","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152474_bib0013","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.3390\/ijms22126211","article-title":"Role of JAK\/STAT in interstitial lung diseases; molecular and cellular mechanisms","volume":"22","author":"Montero","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152474_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103334","article-title":"The interferon in idiopathic inflammatory myopathies: different signatures and new therapeutic perspectives. A literature review","volume":"22","author":"Gasparotto","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152474_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000811","article-title":"Distinct interferon signatures stratify inflammatory and dysimmune myopathies","volume":"5","author":"Rigolet","year":"2019","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152474_bib0016","doi-asserted-by":"crossref","first-page":"e13155","DOI":"10.1111\/bpa.13155","article-title":"Muscle pathology of antisynthetase syndrome according to antibody subtypes","volume":"33","author":"Tanboon","year":"2023","journal-title":"Brain Pathol"},{"key":"10.1016\/j.semarthrit.2024.152474_bib0017","article-title":"Targeting intracellular pathways in idiopathic inflammatory myopathies: a narrative review","volume":"10","author":"La Rocca","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152474_bib0018","first-page":"348","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152474_bib0019","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14939","article-title":"JAK-inhibitors for dermatomyositis: a concise literature review","volume":"34","author":"Paudyal","year":"2021","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152474_bib0020","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/1756-185X.14516","article-title":"Tofacitinib treatment in anti-glycyl-tRNA synthetase antibody interstitial lung disease - A case report","volume":"26","author":"Tseng","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152474_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.585761","article-title":"Iacta Alea Est: the inexorable advance of tofacitinib in the treatment of dermatomyositis-associated rapidly progressive interstitial lung disease. A case report","volume":"11","author":"Conca","year":"2020","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152474_bib0022","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1590\/S1806-37132011000100015","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon","year":"2011","journal-title":"J Bras Pneumol"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152474_bib0023","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1164\/rccm.2106157","article-title":"Acute interstitial pneumonia: comparison of high-resolution computed tomography findings between survivors and nonsurvivors","volume":"165","author":"Ichikado","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152474_bib0024","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40560-021-00566-4","article-title":"The Ichikado CT score as a prognostic tool for coronavirus disease 2019 pneumonia: a retrospective cohort study","volume":"9","author":"Araiza","year":"2021","journal-title":"J Intensive Care"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152474_bib0025","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.resinv.2019.12.003","article-title":"Clinical, radiological, and pathological features of anti-asparaginyl tRNA synthetase antibody-related interstitial lung disease","volume":"58","author":"Aiko","year":"2020","journal-title":"Respir Investig"},{"issue":"9","key":"10.1016\/j.semarthrit.2024.152474_bib0026","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an Update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152474_bib0027","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3390\/jcm8112013","article-title":"Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152474_bib0028","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10067-022-06404-8","article-title":"Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China","volume":"42","author":"Wang","year":"2023","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152474_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label, phase II trial","volume":"10","author":"Allenbach","year":"2015","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.semarthrit.2024.152474_bib0030","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.21037\/jtd-20-3328","article-title":"A narrative review of interstitial lung disease in anti-synthetase syndrome: a clinical approach","volume":"13","author":"Sawal","year":"2021","journal-title":"J Thorac Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2024.152474_bib0031","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","article-title":"Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152474_bib0032","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152474_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103264","article-title":"The role of bDMARDs in idiopathic inflammatory myopathies: a systematic literature review","volume":"22","author":"Grazzini","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2024.152474_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115848","article-title":"Synthesis and clinical application of small-molecule inhibitors of Janus kinase","volume":"261","author":"Zhang","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152474_bib0035","first-page":"e49809","article-title":"The lack of a durable response to tofacitinib in Anti-PL-12 anti-synthetase syndrome with progressive interstitial pneumonitis","volume":"15","author":"Baldawi","year":"2023","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152474_bib0036","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pulmoe.2018.05.008","article-title":"Krebs von den Lungen-6 associated with chest high-resolution CT score in evaluation severity of patients with interstitial lung disease","volume":"25","author":"Qin","year":"2019","journal-title":"Pulmonology"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152474_bib0037","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1148\/radiology.162.2.3797650","article-title":"Usual interstitial pneumonia: correlation of CT with clinical, functional, and radiologic findings","volume":"162","author":"Staples","year":"1987","journal-title":"Radiology"},{"issue":"24","key":"10.1016\/j.semarthrit.2024.152474_bib0038","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152474_bib0039","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/BOR.0000000000000663","article-title":"Pulmonary involvement in antisynthetase syndrome","volume":"31","author":"Gasparotto","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"21","key":"10.1016\/j.semarthrit.2024.152474_bib0040","doi-asserted-by":"crossref","first-page":"6849","DOI":"10.3390\/jcm12216849","article-title":"Clinical characteristics of anti-synthetase syndrome and variables associated with interstitial lung disease and mortality: a retrospective cohort study","volume":"12","author":"Sodsri","year":"2023","journal-title":"J Clin Med"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2024.152474_bib0041","article-title":"The safety of JAK-1 inhibitors","volume":"60","author":"Clarke","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.semarthrit.2024.152474_bib0042","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled Trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152474_bib0043","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3899\/jrheum.221067","article-title":"Ro52, myositis, and interstitial lung disease","volume":"50","author":"McHugh","year":"2023","journal-title":"J Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T20:13:28Z","timestamp":1726604008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224001148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":43,"alternative-id":["S0049017224001148"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152474","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Janus kinase inhibition (JAKi) therapy in refractory anti-synthetase syndrome: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152474"}}